Insulin resistance syndrome: Options for treatment

Southern Medical Journal

Volumn 92, Issue 1, 1999, Pages 1-24

  Granberry, Mark C ^b   Fonseca, Vivian A ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOMOXIR; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DRUG CHOICE; EXERCISE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SYNDROME X; TREATMENT PLANNING; ARTERIOSCLEROSIS; DIABETES MELLITUS; FEMALE; MALE; PHYSIOLOGY; REVIEW;

ARTERIOSCLEROSIS; CHROMANS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MICROVASCULAR ANGINA; OBESITY; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032915085     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. American Diabetes Association: Consensus development conference on insulin resistance. Diabetes Care 1998; 21:310-314
2. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607
3. Denker PS, Pollock VE: Fasting serum insulin levels in essential hypertension, a meta-analysis. Arch Intern Med 1992; 152:1649-1651
4. Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13:1457-1462
5. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381
6. Burchfiel CM, Curb JD, Arakaki R, et al: Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program. Ann Epidemiol 1996; 6:490-497
7. Grunfeld B, Balzareti M, Romo M, et al: Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994; 23(suppl 1):112-115
8. Anonymous: Prevalence of cardiovascular disease risk-factor clustering among persons aged > 45 years - Louisiana, 1991-1995. MMWR 1997; 46:585-588
9. Dagogo-Jack S, Santiago JV: Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997; 157:1802-1817
10. Moller DE, Flier JS: Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938-948
11. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994; 43:1271-1278
12. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:154-1520
13. DeFronzo RA, Ferrannini E: Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194
14. Bjōrntorp P: Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493-496
15. O'Doherty R, Stein D, Foley J: Insulin resistance. Diabetologia 1997; 40(suppl 3):B10-B15
16. Fagard RH: Physical fitness and blood pressure. J Hypertens 1993; 11(suppl 5):S47-S52
17. Chen M, Bergman RN, Pacini G, et al: Pathogenesis of aging-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 1984; 60:13-20
18. Attvall S, Fowelin J, Lager I, et al: Smoking induces insulin resistance - a potential link with the insulin resistance syndrome. J Intern Med 1993; 233:327-332
19. Bōnner G: Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol 1994; 24:S39-S49
20. Deprés J, Moorjani S, Lupien PJ, et al: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10:497-511
21. Abate N: Insulin resistance and obesity: the role of fat distribution pattern. Diabetes Care 1996; 19:292-294
22. Minchoff LE, Grandin JA: Syndrome X: recognition and management of this metabolic disorder in primary care. Nurse Pract 1996; 21:74-75
23. Barbieri RL: Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. J Reprod Med 1994; 39:327-336
24. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223
25. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137:959-965
26. Després JP, Lamarche B, Mauriege P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957
27. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetolagia 1987; 30:123-131
28. Howard G, O'Leary DH, Zaccaro D, et al, for the IRAS investigators: Insulin sensitivity and atherosclerosis. Circulation 1996; 93:1809-1817
29. Gibbons GH: Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79:3-8
30. Yudkin JS: Is insulin vasculotoxic? Diabetologia 1997; 40(suppl 2):S145-S146
31. Steinberg HO, Brechtel G, Johnson A, et al: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest 1994; 94:1172-1179
32. Steinberg HO, Chaker H, Leaming R, et al: Obesity/insulin resistance is associated with endothelial dysfunction: implication for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601-2610
33. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels, a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-462
34. Vague P, Juhan-Vague I, Aillaud MF, et al: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35:250-253
35. Landin K, Tengborn L, Chmielewska J, et al: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991; 65:130-133
36. Nordt TK, Schenider DJ, Sobel BE: Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin, a potential risk factor for vascular disease. Circulation 1994; 89:321-330
37. Collier A, Rumley A, Rumley AG, et al: Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41:909-913
38. Galajda, Martinka E, Mokan M, et al: Endothelial markers in diabetes mellitus. Thromb Res 1997; 85:63-65
39. Godsland IF, Sidhu M, Crook D, et al: Coagulation and fibrinolytic factors, insulin resistance and the metabolic syndrome of coronary heart disease risk (Abstract). Heart 1997; 77(suppl 1):57
40. Kahn CR: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 13:1066-1084
41. Bogardus C, Lillioja S, Howard B, et al: Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non-insulin dependent diabetic subjects. J Clin Invest 1984; 74:1238-1246
42. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15:318-368
43. DeFronzo RA: The triumvirate: β-cell, muscle, liver, a collusion responsible for NIDDM. Diabetes 1988; 37:667-683
44. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334:777-783
45. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197
46. Bhanot S, McNeill JH: Insulin and hypertension: a causal relationship? Cardiovasc Res 1996; 31:212-221
47. Rowe JW, Young JB, Minaker KL, et al: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30:219-225
48. Supiano MA, Hogikyan RV, Morrow LA, et al: Hypertension and insulin resistance: role of sympathetic nervous system activity. Am J Physiol 1992; E935-E942
49. Gaboury CL, Simonson DC, Seely EW, et al: Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest 1994; 94:2295-2300
50. Laakso M, Edelman SV, Brechtel G, et al: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J Clin Invest 1990; 85:1844-1852
51. DeFronzo RA, Cooke CR, Andres R, et al: The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975; 55:845-855
52. Shimamoto K, Hirata A, Fukuoka M, et al: Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23(suppl 1):I29-I33
53. Grundy SM: Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95:1-4
54. Frayn KN: Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993; 4:197-204
55. Boström K, Borén J, Wettesten M, et al: Studies on the assembly of apo-B-100-containing lipoproteins in Hep G2 cells. J Biol Chem 1988; 253:4434-4442
56. Blomhoff JP: Lipoproteins, lipases, and the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992; 20:S22-S25
57. Mahley RW, Weisgraber KH, Farese RV: Disorders of lipid metabolism. Williams Textbook of Endocrinology. Wilson JD, Foster RW, Kronenberg HM, et al (eds). Philadelphia, WB Saunders Co, 9th Ed, 1998, pp 1099-1153
58. Betteridge DJ: LDL heterogeneity: implications for atherogenicity in insulin resistance and NIDDM. Diabetologia 1997; 40:S149-S151
59. Stampfer MJ, Krauss RM, Jing M, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-888
60. Caixàs A, Ordóñez-Llanos J, deLeiva A, et al: Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 1997; 46:1207-1213
61. Gardner GD, Fortman SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875-881
62. Syvänne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350(suppl 1):S120-S123
63. Selwyn AP, Kinlay S, Libby P, et al: Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997; 95:5-7
64. Dunaif A: Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98:33S-39S
65. Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116
66. Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90:392-395
67. American Diabetes Association: Nutritional recommendations and principles for people with diabetes mellitus. Diabetes Care 1997; 20(suppl 1):14-17
68. Edelman SV, Henry RR: Non-insulin-dependent diabetes mellitus. Current Therapy in Endocrinology and Metabolism. Bardin CW (ed). St. Louis, Mosby-Year Book Inc, 6th Ed, 1997, pp 430-438
69. DeFronzo RA, Sherwin RS, Kraemer N: Effect of physical training on insulin action in obesity. Diabetes 1987; 36;1379-1385
70. Segal KR, Edano A, Abalos A, et al: Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. J Appl Physiol 1991; 71:2402-2411
71. Perseghin G, Price TB, Petersen KF, et al: Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin resistant subjects. N Engl J Med 1996; 335:1357-1362
72. Goodyear LJ, Hirshman MF, Valyou PM, et al: Glucose transporter number, function, and subcellular distribution in rat skeletal muscle after exercise training. Diabetes 1992; 41:1091-1099
73. Niskanen L, Uusitupa M, Sarlund H, et al: The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int J Obes Relat Metab Disord 1996; 20:154-160
74. Hoffman RP, Stumbo PJ, Janz KF, et al: Altered insulin resistance is associated with increased dietary weight loss in obese children. Horm Res 1995; 44:17-22
75. Velthuis-te Wierik EJ, Meijer P, Kluft C, et al: Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men. Metabolism 1995; 44:1548-1552
76. Ikeda T, Gomi T, Hirawa N, et al: Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension 1996; 27:1180-1186
77. Kern PA, Saghizadeh M, Ong JM, et al: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119
78. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996; 334:574-579
79. Bailey CJ: Biguanides and NIDDM. Diabetes Care 1992; 15:755-772
80. Fery F, Plat L, Balasse EO: Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997; 46:227-233
81. Stumvoll M, Nurjhan N, Perriello G, et al: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-554
82. Inzucchi SE, Maggs DG, Spollett GR, et al: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872
83. Fanghānel G, Sánchez-Reyes L, Trujillo C, et al: Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996; 19:1185-1189
84. Wu MS, Johnston P, Sheu WHH, et al: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13:1-8
85. Baliga BS, Fonseca VA: Recent advances in the treatment of type II diabetes mellitus. Am Fam Phys 1997; 55:817-824
86. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-549
87. Garber AJ, Duncan TG, Goodman AM, et al: Efficacy of metformin in type II diabetes: results of a double-blind, placebo controlled, dose-response trial. Am J Med 1997; 102:491-497
88. Sulkin TV, Bosman D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20:925-928
89. Willson TM, Cobb JE, Cowan DJ, et al: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39:665-668
90. Saltiel AR, Olefsky JM: Perspectives in diabetes: thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45:1661-1669
91. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:193-203
92. Mimura K, Umeda F, Hiramatsu S, et al: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 1994; 11:685-691
93. Kumar S, Boulton AJM, Beck-Nielson H, et al: Troglitazone, an insulin enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39:701-709
94. Raskin P, Graveline JF: Efficacy of troglitazone in combination with insulin in NIDDM (Abstract). Diabetes 1997; 46:44A
95. Schwartz S, Raskin P, Fonseca V, et al: Effect of troglitazone in insulin-treated patients with type 2 diabetes. N Engl J Med 1998; 338:861-866
96. Maggs DG, Buchanan TA, Burant CF, et al: Ann Intern Med 1998; 128:176-185
97. Fonseca V, Valiquett TR, Whitcomb R: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; (In press)
98. Iwamoto Y, Kosaka K, Kuzuya T, et al: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156
99. Valiquett T, Huang S, Whitcomb R: Effects of troglitazone monotherapy in patients with NIDDM: a 6 month multicenter study (Abstract). Diabetes 1997; 46:43A
100. Ghazzi MN, Perez JE, Antonucci TK, et al: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46:433-439
101. Cominacini L, Garbin U, Pasini AF, et al: Troglitazone increases the resistance of LDL to oxidation in healthy volunteers (Abstract). Diabetologia 1996; 39:A233
102. Ogihara T, Rakugi H, Ikegami H, et al: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320
103. Antonucci T, Whitcomb R, McLain R, et al: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20:188-193
104. Sironi AM, Vichi S, Gastaldelli A, et al: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202
105. Akanuma Y, Kosaka T, Toyoda T, et al: Clinical evaluation of a new oral hypoglycemic agent CS-045 in combination with insulin (Abstract). Diabetologia 1996; 39:A232
106. Iwamoto Y, Kuzuya T, Matsuda A, et al: Effect of a new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14:1083-1086
107. Fonseca V, Reynolds T, Hemphill D, et al: Effect of troglitazone on fibrinolysis and coagulation (Abstract). Diabetes 1997; 46:93A
108. Rezulin Physician's Monograph. Morris Plains, NJ, Parke-Davis, 1997
109. Slaughter RL, Edwards DJ: Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29:619-624
110. Clissold SP, Edwards C: Acarbose, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35:214-243
111. Mathur S, Fonseca V, Dandona P: The effect of miglitol on insulin sensitivity in NIDDM (Abstract). Diabetes 1991; 40:336A
112. Foley JE: Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15:773-784
113. Hübinger A, Weikert G, Wolf HPO, et al: The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metab Res 1992; 24:115-118
114. Müller G, Wied S: The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993; 42:1852-1867
115. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998; 21(suppl 1):S23-S31
116. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21:160-178
117. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023
118. Lean MEJ: Sibutramine - a review of clinical efficacy. Int J Obes 1997; 21:S30-S36
119. Griffiths J, Drynes AE, Frost G, et al: Sibutramine in the treatment of overweight non-insulin dependent diabetics (Abstract). Int J Obes 1995; 19(suppl 2):41
120. Nolan JJ, Ludvik B, Beerdsen P, et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188-1193
121. Berkowitz K, Peters R, Kjos SL, et al: Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 1996; 45:1572-1579
122. Giugliano D, DeRosa N, DiMaro G, et al: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16:1387-1390
123. Linday LA: Trivalent chromium and the diabetes prevention program. Med Hypotheses 1997; 49:47-49